BIO.B vs. KEYS, FTV, VLTO, TER, AVTR, RVTY, NVMI, VNT, ST, and CAMT
Should you be buying Bio-Rad Laboratories stock or one of its competitors? The main competitors of Bio-Rad Laboratories include Keysight Technologies (KEYS), Fortive (FTV), Veralto (VLTO), Teradyne (TER), Avantor (AVTR), Revvity (RVTY), Nova (NVMI), Vontier (VNT), Sensata Technologies (ST), and Camtek (CAMT). These companies are all part of the "measuring and control equipment" industry.
Bio-Rad Laboratories vs.
Bio-Rad Laboratories (NYSE:BIO.B) and Keysight Technologies (NYSE:KEYS) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their dividends, analyst recommendations, earnings, media sentiment, institutional ownership, community ranking, valuation, profitability and risk.
Bio-Rad Laboratories has a beta of 0.72, indicating that its share price is 28% less volatile than the S&P 500. Comparatively, Keysight Technologies has a beta of 1.02, indicating that its share price is 2% more volatile than the S&P 500.
Keysight Technologies received 348 more outperform votes than Bio-Rad Laboratories when rated by MarketBeat users. Likewise, 65.97% of users gave Keysight Technologies an outperform vote while only 57.60% of users gave Bio-Rad Laboratories an outperform vote.
In the previous week, Keysight Technologies had 20 more articles in the media than Bio-Rad Laboratories. MarketBeat recorded 21 mentions for Keysight Technologies and 1 mentions for Bio-Rad Laboratories. Keysight Technologies' average media sentiment score of 1.08 beat Bio-Rad Laboratories' score of 0.00 indicating that Keysight Technologies is being referred to more favorably in the news media.
0.0% of Bio-Rad Laboratories shares are owned by institutional investors. Comparatively, 84.6% of Keysight Technologies shares are owned by institutional investors. 28.4% of Bio-Rad Laboratories shares are owned by company insiders. Comparatively, 0.6% of Keysight Technologies shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Keysight Technologies has a consensus target price of $180.80, indicating a potential upside of 5.58%. Given Keysight Technologies' stronger consensus rating and higher possible upside, analysts plainly believe Keysight Technologies is more favorable than Bio-Rad Laboratories.
Keysight Technologies has higher revenue and earnings than Bio-Rad Laboratories. Bio-Rad Laboratories is trading at a lower price-to-earnings ratio than Keysight Technologies, indicating that it is currently the more affordable of the two stocks.
Keysight Technologies has a net margin of 12.32% compared to Bio-Rad Laboratories' net margin of -30.18%. Keysight Technologies' return on equity of 19.22% beat Bio-Rad Laboratories' return on equity.
Summary
Keysight Technologies beats Bio-Rad Laboratories on 17 of the 18 factors compared between the two stocks.
Get Bio-Rad Laboratories News Delivered to You Automatically
Sign up to receive the latest news and ratings for BIO.B and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
BIO.B vs. The Competition
Bio-Rad Laboratories Competitors List
Related Companies and Tools
This page (NYSE:BIO.B) was last updated on 1/22/2025 by MarketBeat.com Staff
Free BIO.B Stock Alerts